FDA 483 - Rio Biofarma Brasil Ltda - May 09, 2024
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of RIO BIOFARMA BRASIL LTDA in Hortolandia, Sao Paulo, a sterile drug manufacturer, revealed significant deficiencies in laboratory controls, process validation, and quality control procedures. The firm failed to establish adequate specifications, prevent microbiological contamination, thoroughly investigate discrepancies, and properly revalidate processes. These issues collectively indicate a serious lack of control over drug product identity, strength, quality, and purity.
ID · cd70d835-9e3b-455c-9f02-6fd8d2dc5496